Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K49/00—Preparations for testing in vivo
  • A61K49/001—Preparation for luminescence or biological staining
  • A61K49/0013—Luminescence
  • A61K49/0017—Fluorescence in vivo
  • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
  • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
  • A61K49/0032—Methine dyes, e.g. cyanine dyes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
  • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K49/00—Preparations for testing in vivo
  • A61K49/001—Preparation for luminescence or biological staining
  • A61K49/0013—Luminescence
  • A61K49/0017—Fluorescence in vivo
  • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
  • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
  • A61K49/0032—Methine dyes, e.g. cyanine dyes
  • A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K49/00—Preparations for testing in vivo
  • A61K49/001—Preparation for luminescence or biological staining
  • A61K49/0013—Luminescence
  • A61K49/0017—Fluorescence in vivo
  • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
  • A61K49/0052—Small organic molecules
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K49/00—Preparations for testing in vivo
  • A61K49/001—Preparation for luminescence or biological staining
  • A61K49/0013—Luminescence
  • A61K49/0017—Fluorescence in vivo
  • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
  • A61K49/0056—Peptides, proteins, polyamino acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/04—Antineoplastic agents specific for metastasis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
  • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
  • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
  • C09B23/0066—Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain being part of a carbocyclic ring,(e.g. benzene, naphtalene, cyclohexene, cyclobutenene-quadratic acid)
• • C—CHEMISTRY; METALLURGY
  • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
  • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
  • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
  • C09B23/0075—Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain being part of an heterocyclic ring

Definitions

• This invention relates to novel dye-bioconjugates for use in diagnosis and therapy, particularly novel compositions of cyanine dye bioconjugates of bioactive molecules.
• Cancer will continue to be a primary cause of death for the foreseeable future, but early detection of tumors would improve patient prognosis (R. T. Greenlee et al., Cancer statistics. 2000. CA Cancer J. Clin., 2000, 50, pp. 7-33).
• R. T. Greenlee et al. Cancer statistics. 2000. CA Cancer J. Clin., 2000, 50, pp. 7-33.
• physicians still rely on the presence of a palpable tumor mass. At this, however, the many benefits of early medical intervention may have been already compromised.
• Photodiagnosis and/or phototherapy has a great potential to improve management of cancer patient (D. A. Benaron and D. K. Stevenson, Optical time-of-fliqht and absorbance imaging of biologic media. Science, 1993, 259, pp. 1463-1466; R. F. Potter (Series Editor), Medical optical tomography: functional imaging and monitoring, SPIE Optical Engineering Press, Bellingham, 1993; G. J. Tearney et al., In vivo endoscopic optical biopsy with optical coherence tomography. Science, 1997, 276, pp. 2037-2039; B. J. Tromberg et al., Non-invasive measurements of breast tissue optical properties using frequency-domain photon migration. Phil. Trans.
• Dyes are important to enhance signal detection and/or photosensitizing of tissues in optical imaging and phototherapy. Previous studies have shown that certain dyes can localize in tumors and serve as a powerful probe for the detection and treatment of small cancers (D. A. Bellnier et al., Murine pharmacokinetics and antitumor efficacy of the photodynamic sensitizer 2-f1-hexyloxyethyl1-2-devinyl pyropheophorbide-a. J. Photochem. Photobiol, 1993, 20, pp. 55-61 ; G. A. Wagnieres et al., In vivo fluorescence spectroscopy and imaging for oncological applications. Photochem. Photobiol,
• the invention is directed to a composition for a carbocyanine dye bioconjugate.
• the bioconjugate consists of three components: 1) a tumor specific agent, 2) a photosensitizer (phototherapy) agent, and 3) a photodiagnostic agent.
• the inventive bioconjugates use the multiple attachment points of carbocyanine dye structures to incorporate one or more receptor targeting and/or photosensitive groups in the same molecule.
• the composition may be used in various biomedical applications.
• the invention is also directed to a method for performing a diagnostic and therapeutic procedure by administering an effective amount of the composition of the cyanine dye bioconjugate to an individual.
• the method may be used in various biomedical applications, such as imaging tumors, targeting tumors with anti-cancer drugs, and performing laser guided surgery.
• Fig 1. shows representative structures of the inventive compounds.
• Fig. 2 shows images taken at two minutes and 30 minutes post injection of indocyanine green into rats with various tumors.
• Fig. 3 shows fluorescent images of a CA20948 tumor bearing rat taken at one and 45 minutes post administration of cytate.
• Fig. 4 is a fluorescent image of a CA20948 tumor bearing rat taken at 27 hours post administration of cytate.
• Fig. 5 shows fluorescent images of ex-vivo tissues and organs from a CA20948 tumor bearing rat at 27 hours post administration of cytate.
• Fig. 6 is a fluorescent image of an AR42-J tumor bearing rat taken at 22 hours post administration of bombesinate.
• the invention relates to novel compositions comprising cyanine dyes having a general formula 1
• W 1 and W 2 may be the same or different and are selected from the group consisting of -CR 10 R 11 , -0-, -NR 12 , -S-, and -Se; Y 1 f Y 2 , Z , and Z 2 are independently selected from the group consisting of hydrogen, tumor-specific agents, phototherapy agents, -CONH-Bm, -NHCO-Bm, -(CH 2 ) a -CONH-Bm, -CH 2 -(CH 2 OCH 2 ) b -CH 2 -CONH-Bm, -(CH 2 ) a -NHCO-Bm, -CH 2 -(CH 2 OCH 2 ) b -CH 2 - NHCO-Bm, -(CH 2 ) a -N(R 12 )-(CH 2 ) b -CONH-Bm, -(CH 2 ) a -N(R 12 HCH 2 ) c -NHCO
• the invention also relates to the novel composition comprising carbocyanine dyes having a general formula 2
• the invention also relates to the novel composition comprising carbocyanine dyes having a general formula 3
• Formula 3 wherein A 1 is a single or a double bond; B 1 f C,, and D 1 are independently selected from the group consisting of -0-, -S-, -Se-, -P-, -CR 10 R 11 , -CR 11 , alkyl, NR 12 , and -C 0; A.,, B.,, C,, and D., may together form a 6- to 12-membered carbocyclic ring or a 6- to 12-membered heterocyclic ring optionally containing one or more oxygen, nitrogen, or sulfur atoms; and W.,, W 2 , Y 1f Y 2 , Z.,, Z 2 , , K 2 , X X 2 , a,, b 1f and R 1 to R 12 are defined in the same manner as in Formula 1.
• the present invention also relates to the novel composition comprising carbocyanine dyes having a general formula 4
• a 1 f B.,, C,, and D 1 are defined in the same manner as in Formula 3; W 17 W 2 , Yi, Y 2 , Z ⁇ - ⁇ , Z 2 , K.,, K 2 , X.,, X 2 , a , and b 1 are defined in the same manner as in Formula 1 ; and R 19 to R 31 are defined in the same manner as R 1 to R 9 in Formula 1.
• the inventive bioconjugates use the multiple attachment points of carbocyanine dye structures to incorporate one or more receptor targeting and/or photosensitive groups in the same molecule. More specifically, the inventive compositions consist of three components selected for their specific properties. One component, a tumor specific agent, is for targeting tumors.
• a second component which may be a photosensitizer, is a phototherapy agent.
• a third component is a photodiagnostic agent.
• the tumor targeting agents are bioactive peptides such as octreotate and bombesin (7-14) which target overexpressed receptors in neuroendocrine tumors.
• photodiagnostic agents are carbocyanine dyes which have high infrared molar absorbtivities ( Figure 1A-C).
• the invention provides each of these components, with their associated benefits, in one molecule for an optimum effect.
• Such small dye biomolecule conjugates have several advantages over either nonspecific dyes or the conjugation of probes or photosensitive molecules to large biomolecules. These conjugates have enhanced localization and rapid visualization of tumors which is beneficial for both diagnosis and therapy. The agents are rapidly cleared from blood and non- target tissues so there is less concern for accumulation and for toxicity. A variety of high purity compounds may be easily synthesized for combinatorial screening of new targets, e.g., to identify receptors or targeting agents, and for the ability to affect the pharmacokinetics of the conjugates by minor structural changes.
• inventive compositions are useful for various biomedical applications. Examples of these applications include, but are not limited to: detecting, imaging, and treating of tumors; tomographic imaging of organs; monitoring of organ functions; performing coronary angiography, fluorescence endoscopy, laser guided surgery; and performing photoacoustic and sonofluorescent methods.
• inventive dyes are prepared according the methods well known in the art.
• the inventive bioconjugates have the formulas 1 or 2 where W., and W 2 may be the same or different and are selected from the group consisting of -C(CH 3 ) 2 , -C((CH 2 ) a OH)CH 3 , -C((CH 2 ) a OH) 2 , -C((CH 2 ) a C0 2 H)CH 3 , -C((CH 2 ) a C0 2 H) 2 , -C((CH 2 ) a NH 2 )CH 3 , -C((CH 2 ) a NH 2 ) 2 , -C((CH 2 ) a NR 12 R 13 ) 2 , -NR 12 , and -S-; Y, and Y 2 are selected from the group consisting of hydrogen, tumor-specific agents, -CONH-Bm, -NHCO- Bm, -(CH 2 ) a -CONH-Bm, -
• ⁇ and K 2 are independently selected from the group consisting of C r C 10 alkyl, C 5 -C 20 aryl, C r C 20 alkoxyl, C r C 20 aminoalkyl, -(CH 2 ) a -CO-, -(CH 2 ) a -CONH, -CH 2 -(CH 2 OCH 2 ) b - CH 2 -CONH-, -(CH 2 ) a -NHCO-, -CH 2 -(CH 2 OCH 2 ) )
• the bioconjugates according to the present invention have the formulas 3 or 4 wherein W 1 and W 2 may be the same or different and are selected from the group consisting of -C(CH 3 ) 2 , -C((CH 2 ) a OH)CH 3 , -C((CH 2 ) a OH) 2 , -C((CH 2 ) a C0 2 H)CH 3 , -C((CH 2 ) a C0 2 H) 2 , -C((CH 2 ) a NH 2 )CH 3 , -C((CH 2 ) a NH 2 ) 2 , -C((CH 2 ) a NR 12 R 13 ) 2 , -NR 12 , and -S-; and Y 2 are selected from the group consisting of hydrogen, tumor-specific agents, -CONH-Bm, -NHCO-Bm, -(CH 2 ) a -CONH-Bm,
• the dye-biomolecule conjugates are useful for optical tomographic, endoscopic, photoacoustic and sonofluorescent applications for the detection and treatment of tumors and other abnormalities. These methods use light of wavelengths in the region of 300-1300 nm.
• OCT optical coherence tomography
• OCT methods use wavelengths of about 1280 nm.
• the dye-biomolecule conjugates are useful for localized therapy for the detection of the presence or absence of tumors and other pathologic tissues by monitoring the blood clearance profile of the conjugates, for laser assisted guided surgery (LAGS) for the detection and treatment of small micrometastases of tumors, e.g., somatostatin subtype 2 (SST-2) positive tumors, upon laparoscopy, and for diagnosis of atherosclerotic plaques and blood clots.
• LAGS laser assisted guided surgery
• a therapeutic procedure comprises attaching a porphyrin or photodynamic therapy agent to a bioconjugate, and then administering light of an appropriate wavelength for detecting and treating an abnormality.
• compositions of the invention can be formulated for enteral or parenteral administration.
• These formulations contain an effective amount of the dye-biomolecule conjugate along with conventional pharmaceutical carriers and excipients appropriate for the type of administration contemplated.
• parenteral formulations advantageously contain a sterile aqueous solution or suspension of the inventive conjugate, and may be injected directly, or may be mixed with a large volume parenteral composition or excipient for systemic administration as is known to one skilled in the art.
• These formulations may also contain pharmaceutically acceptable buffers and/or electrolytes such as sodium chloride.
• Formulations for enteral administration may vary widely, as is well known in the art.
• such formulations are aqueous solutions, suspensions or emulsions which contain an effective amount of a dye- biomolecule conjugate.
• Such enteral compositions may include buffers, surfactants, thixotropic agents, and the like.
• Compositions for oral administration may also contain flavoring agents and other ingredients for enhancing their organoleptic qualities.
• the inventive compositions of the carbocyanine dye bioconjugates for diagnostic uses are administered in doses effective to achieve the desired effect.
• Such doses may vary widely, depending upon the particular conjugate employed, the organs or tissues which are the subject of the imaging procedure, the imaging equipment being used, and the like.
• the compositions may be administered either systemically, or locally to the organ or tissue to be imaged, and the patient is then subjected to diagnostic imaging and/or therapeutic procedures.
• Example 2 About 5 ml of a wate ⁇ acetonitrile (3:2 V ) mixture was added to the solid residue and lyophilized to obtain 2 g of dark green flakes. The purity of the compound was established with 1 H-nuclear magnetic resonance ( 1 H-NMR) and liquid chromatography/mass spectrometry (LC/MS) as is known to one skilled in the art.
• 1 H-NMR 1 H-nuclear magnetic resonance
• LC/MS liquid chromatography/mass spectrometry
• Octreotate an octapeptide, has the amino acid sequence D-Phe- Cys'-Tyr-D-Trp-Lys-Thr-Cys'-Thr (SEQ ID NO:1), wherein Cys' indicates the presence of an intramolecular disulfide bond between two cysteine amino acids.
• Octreotate was prepared by an automated fluorenylmethoxycarbonyl (Fmoc) solid phase peptide synthesis using a commercial peptide synthesizer from Applied Biosystems (Model 432A SYNERGY Peptide Synthesizer). The first peptide cartridge contained Wang resin pre-loaded with Fmoc-Thr on a 25- ⁇ mole scale.
• Fmoc fluorenylmethoxycarbonyl
• Subsequent cartridges contained Fmoc-protected amino acids with side chain protecting groups for the following amino acids: Cys(Acm), Thr(t-Bu), Lys(Boc), Trp(Boc) and Tyr(t-Bu).
• the amino acid cartridges were placed on the peptide synthesizer and the product was synthesized from the C- to the N-terminal position according to standard procedures.
• the coupling reaction was carried out with 75 ⁇ moles of the protected amino acids in the presence of 2-(1 H-benzotriazol-1-yl)-1 ,1 ,3,3-tetramethyluronium hexafluorophosphate (HBTU)/N-hydroxybenzotriazole (HOBt).
• HBTU 2-(1 H-benzotriazol-1-yl)-1 ,1 ,3,3-tetramethyluronium hexafluorophosphate
• HBt 2-(1 H-benzotriazol-1-yl)-1
• the Fmoc protecting groups were removed with 20% piperidine in dimethylformamide. After the synthesis was complete, the thiol group was cyclized with thallium trifluoroacetate and the product was cleaved from the solid support with a cleavage mixture containing trifluoroacetic acid watenphenohthioanisole (85:5:5:5 V/V ) for 6 hours.
• the peptide was precipitated with t-butyl methyl ether and lyophilized with wate ⁇ acetonitrile (2:3 V/V ). The peptide was purified by HPLC and analyzed by LC/MS.
• Octreotide (D-Phe-Cys'-Tyr-D-Trp-Lys-Thr-Cys'-Thr-OH (SEQ ID NO:2)), wherein Cys' indicates the presence of an intramolecular disulfide bond between two cysteine amino acids) was prepared by the same procedure as that for octreotate with no modifications.
• Bombesin analogs were prepared by the same procedure but cyclization with thallium trifluoroacetate was omitted. Side-chain deprotection and cleavage from the resin was carried out with 50 ⁇ l each of ethanedithiol, thioanisole and water, and 850 ⁇ l of trifluoroacetic acid. Two analogues were prepared: Gly-Ser-Gly-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH 2 (SEQ ID NO:3) and Gly-Asp-Gly-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH 2 (SEQ ID NO:4).
• Cholecystokinin octapeptide analogs were prepared as described for Octreotate without the cyclization step. Three analogs were prepared: Asp-
• Tyr-Met-Gly-Trp-Met-Asp-Phe-NH 2 (SEQ ID NO:5); Asp-Tyr-Nle-Gly-Trp-Nle-
• Asp-Phe-NH 2 SEQ ID NO:6; and D-Asp-Tyr-Nle-Gly-Trp-Nle-Asp-Phe-NH 2
• Neurotensin analog (D-Lys-Pro-Arg-Arg-Pro-Tyr-lle-Leu (SEQ ID NO:8)) was prepared as described for Octreotate without the cyclization step.
• Octreotate was prepared as described in Example 3, but the peptide was not cleaved from the solid support and the N-terminal Fmoc group of Phe was retained. The thiol group was cyclized with thallium trifluoroacetate and Phe was deprotected to liberate the free amine.
• Bisethylcarboxymethylindocyanine dye 53 mg, 75 ⁇ moles was added to an activation reagent consisting of a mixture 0.2 M HBTU/HOBt in DMSO (375 ⁇ l), and 0.2 M diisopropylethylamine in DMSO (375 ⁇ l). The activation was complete in about 30 minutes. The resin-bound peptide (25 ⁇ moles) was then added to the dye. The coupling reaction was carried out at ambient temperature for 3 hours. The mixture was filtered and the solid residue was washed with DMF, acetonitrile and THF. After drying the green residue, the peptide was cleaved from the resin, and the side chain protecting groups were removed with a mixture of trifluoroacetic acid: water:thioanisole:phenol
• the monooctreotate conjugate may be obtained almost exclusively (>95%) over the bis conjugate by reducing the reaction time to 2 hours. This, however, leads to an incomplete reaction, and the free octreotate must be carefully separated from the dye conjugate in order to avoid saturation of the receptors by the non-dye conjugated peptide.
• Octreotate-bispentylcarboxymethylindocyanine dye was prepared as described in Example 4 with some modifications.
• Bispentylcarboxymethylindocyanine dye 60 mg, 75 ⁇ moles was added to 400 ul activation reagent consisting of 0.2 M HBTU/HOBt and 0.2 M of diisopropylethylamine in DMSO. The activation was complete in about 30 minutes and the resin-bound peptide (25 ⁇ moles) was added to the dye. The reaction was carried out at ambient temperature for 3 hours. The mixture was filtered and the solid residue was washed with DMF, acetonitrile and THF.
• the peptide was cleaved from the resin and the side chain protecting groups were removed with a mixture of trifluoroacetic acid:water:thioanisole:phenol (85:5:5:5 V/V )
• the resin was filtered and cold t-butyl methyl ether (MTBE) was used to precipitate the dye-peptide conjugate.
• the conjugate was dissolved in acetonitrile:water (2:3 V/V ) and lyophilized.
• Bispentylcarboxymethylindocyanine dye (cyhex, 60 mg, 75 ⁇ moles) in dichloromethane is reacted with cyanuric acid fluoride (21 mg, 150 mmoles) in the presence of pyridine (12 mg, 150 mmoles) for 30 minutes to produce an acid anhydride.
• cyanuric acid fluoride 21 mg, 150 mmoles
• pyridine 12 mg, 150 mmoles
• This intermediate is added to an activation reagent consisting of a 0.2 M solution of HBTU/HOBt in DMSO (400 ⁇ l), and a 0.2 M solution of diisopropylethylamine in DMSO (400 ⁇ l). Activation of the carboxylic acid is complete in about 30 minutes.
• Resin-bound peptide (octreotate, 25 ⁇ moles), is prepared as described in Example 4, is added to the mixture. The reaction is carried out at ambient temperature for 8 hours. The mixture is filtered at the solid residue is washed with DMF, acetonitrile and THF.
• the peptide derivative is cleaved from the resin and the side chain protecting groups are removed with a mixture of trifluoroacetic acid:water:thioanisole:phenol (85:5:5:5 V/V ).
• cold t-butyl methyl ether (MTBE) is used to precipitate the dye-peptide conjugate, which is then lyophilized in acetonitrile:water (2:3 V/V ).
• a non-invasive in vivo fluorescence imaging apparatus was employed to assess the efficacy of indocyanine green (ICG) in three different rat tumor cell lines of the inventive contrast agents developed for tumor detection in animal models.
• ICG indocyanine green
• the detector was a Princeton Instruments model RTE/CCD-1317-K/2 CCD camera with a Rodenstock 10 mm F2 lens (stock #542.032.002.20) attached.
• An 830 nm interference lens (CVI Laser Corp., part # F10-830-4-2) was mounted in front of the CCD input lens, such that only emitted fluorescent light from the contrast agent was imaged.
• DSL 6/A pancreatic
• Dunning R3327-H prostate
• CA20948 pancreatic
• SST-2 somatostatin receptors
• the animals were anesthetized with xylazine:ketamine:acepromazine (1.5:1.5:0.5 V/V ) at 0.8 ml/kg via intramuscular injection.
• the left flank was shaved to expose the tumor and surrounding surface area.
• a 21 -gauge butterfly needle equipped with a stopcock connected to two syringes containing heparinized saline was placed into the tail vein of the rat. Patency of the vein was checked prior to administration of ICG.
• Each animal was administered a 0.5 ml dose of a 0.42 mg/ml solution of ICG in saline.
• the first two tumor lines were not as highly vascularized as CA20948 which is also rich in somatostatin (SST-2) receptors. Consequently, the detection and retention of a dye in the CA20948 tumor model is an important index of receptor-mediated specificity.
• the peptide, octreotate is known to target somatostatin (SST-2) receptors. Therefore, the cyano-octreotates conjugate, Cytate 1 , was prepared as described in Example 4.
• the pancreatic acinar carcinoma, CA20948, was induced into male Lewis rats as described in Example 9.
• the animals were anesthetized with xylazine: ketamine: acepromazine (1.5: 1.5: 0.5 V/V ) at 0.8 ml/kg via intramuscular injection.
• the left flank was shaved to expose the tumor and surrounding surface area.
• a 21- gauge butterfly needle equipped with a stopcock connected to two syringes containing heparinized saline was placed into the tail vein of the rat. Patency of the vein was checked prior to administration of Cytate 1 via the butterfly apparatus. Each animal was administered a 0.5 ml dose of a 1.0 mg/ml solution of Cytate 1 in 25% (v/v) dimethylsulfoxide/ water.
• the AR42-J cell line is derived from exocrine rat pancreatic acinar carcinoma. It can be grown in continuous culture or maintained in vivo in athymic nude mice, SCID mice, or in Lewis rats. This cell line is particularly attractive for in vitro receptor assays, as it is known to express a variety of hormone receptors including cholecystokinin (CCK), epidermal growth factor (EGF), pituitary adenylate cyclase activating peptide (PACAP), somatostatin (sst 2 ) and bombesin.
• CCK cholecystokinin
• EGF epidermal growth factor
• PACAP pituitary adenylate cyclase activating peptide
• sst 2 somatostatin
• Fluorescence endoscopy is suitable for tumors or other pathologic conditions of any cavity of the body. It is very sensitive and is used to detect small cancerous tissues, especially in the lungs and gastrointestinal (Gl) system. Methods and procedures for fluorescence endoscopy are well- documented [Tajiri H., et al. Fluorescent diagnosis of experimental gastric cancer using a tumor-localizing photosensitizer. Cancer Letters (1997) 111 ,
• the fluorescence endoscope consists of a small optical fiber probe inserted through the working channel of a conventional endoscope.
• Some fibers within this probe deliver the excitation light at 780 nm and others detect the fluorescence from the injected optical probe at 830 nm. The fluorescence intensity is displayed on a monitor.
• the CA20948 rat pancreatic tumor cells which are over- expressing somatostatin receptor are injected into the submucosa of a Lewis rat.
• the tumor is allowed to grow for two weeks.
• the rat is then anesthetized with xylazine : ketamine : acepromazine (1.5 : 1.5 : 0.5 V/V ) at 0.8 mL/kg via intramuscular injection.
• Cytate is injected in the tail vein of the rat and 60 minutes post-injection, the endoscope is inserted into the Gl tract. Since cytate localizes in CA20948, the fluorescence intensity in the tumor is much higher than in the surrounding normal tissues.
• the relative position of the tumor is determined by observing the image on a computer screen.
• the photoacoustic imaging technique combines optical and acoustic imaging to allow better diagnosis of pathologic tissues.
• the preferred acoustic imaging method is ultrasonography where images are obtained by irradiating the animal with sound waves.
• the dual ultrasonography and optical tomography enables the imaging and localization of pathologic conditions (e.g., tumors) in deep tissues.
• pathologic conditions e.g., tumors
• cytate is incorporated into ultrasound contrast material. Methods for the encapsulation of gases in biocompatible shells that are used as the contrast material are described in the literature [Mizushige K., et al. Enhancement of ultrasound-accelerated thrombolysis by echo contrast agents: dependence on microbubble structure. Ultrasound in Med. & Biol. (1999), 25, 1431-1437].
• perfluorocarbon gas e.g., perfluorobutane
• perfluorocarbon gas e.g., perfluorobutane
• normal saline propylene glycol : glycerol (7 : 1.5 : 1.5 V/V/V ) containing 7 mg/ml of cytate : dipalmitoylphosphatidylcholine : dipalmitoylphosphatidic acid, and dipalmitoylphosphatidylethanolamine-PEG 5,000 (1 : 7 : 1 : 1 mole %).
• the CA20948 tumor bearing Lewis rat is injected with 1 ml of the microbubbles and the agent is allowed to accumulate in the tumor.
• An optical image is obtained by exciting the near infrared dye at 780 nm and detecting the emitted light at 830 nm, as described in Examples 9-11.
• Ultrasonography is performed by irradiating the rat with sound waves in the localized tumor region and detecting the reflected sound as described in the literature [Peter J. A. Frinking, Ayache
• m-hydroxyphenylchlorin (m-hydroxyphenyl)chlorin (mTHPC): Influence of Light Intensity and Optimization of Photodynamic Efficiency. Proc. SPIE (1996), 2924, 181-186;
• a solution of the peptide-dye-phototherapy bioconjugate is prepared as described in Example 7 (5 ⁇ mol/mL of 15% DMSO in water, 0.5 mL) and is injected into the tail vein of the tumor-bearing rat. The rat is imaged 24 hours post injection as described in Examples 9-11 to localize the tumor. Once the tumor region is localized, the tumor is irradiated with light of 700 nm (which corresponds to the maximum absorption wavelength of HPPH, the component ' of the conjugate that effects PDT).
• the energy of radiation is 10 J/cm 2 at 160 mW/cm 2 .
• the laser light is transmtited through a fiber optic, which is directed to the tumor.
• the rat is observed for 7 days and any decrease in tumor volume is noted. If the tumor is still present, a second dose of irradiation is repeated as descried above until the tumor is no longer palpable.
• a diagnostic amount of cytate (0.5 mL/0.2 Kg rat) is injected into the tail vein of the tumor-bearing rat and optical images are obtained as described in Examples 9-11.
• a solution of the peptide-dye- phototherapy bioconjugate is prepared as described in Example 7 (5 ⁇ mol/mL of 15% DMSO in water, 1.5 mL) and is injected directly into the tumor. The tumor is irradiated as described above.
• a solution of a peptide-dye-bioconjugate for targeting atherosclerotic plaques and associated blood clots is prepared as described in Example 7.
• the procedure for injecting the bioconjugate and subsequent localization and diagnosis of the plaques and clots is performed as described in Example 14.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Engineering & Computer Science (AREA)
• Epidemiology (AREA)
• Chemical & Material Sciences (AREA)
• Biomedical Technology (AREA)
• Organic Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Molecular Biology (AREA)
• Biochemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Urology & Nephrology (AREA)
• Cardiology (AREA)
• Vascular Medicine (AREA)
• Heart & Thoracic Surgery (AREA)
• Oncology (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Indole Compounds (AREA)
• Peptides Or Proteins (AREA)
• Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
• Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
• Investigating Or Analysing Materials By Optical Means (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Publications (2)

Family

ID=25528252

Family Applications (1)

Country Status (6)

Cited By (3)

Families Citing this family (7)

Family Cites Families (18)

• 2001
  • 2001-10-17 US US09/981,271 patent/US20030105300A1/en not_active Abandoned
• 2002
  • 2002-10-07 AU AU2002334891A patent/AU2002334891A1/en not_active Abandoned
  • 2002-10-07 JP JP2003535708A patent/JP2005526863A/ja active Pending
  • 2002-10-07 EP EP10075038A patent/EP2201897A3/en not_active Withdrawn
  • 2002-10-07 EP EP02801661A patent/EP1443861A4/en not_active Withdrawn
  • 2002-10-07 CA CA002463911A patent/CA2463911A1/en not_active Abandoned
  • 2002-10-07 WO PCT/US2002/032022 patent/WO2003032902A2/en not_active Ceased

Also Published As

Similar Documents

Legal Events